Comparative Pharmacology
Head-to-head clinical analysis: AMITRIL versus IMIPRAMINE PAMOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITRIL versus IMIPRAMINE PAMOATE.
AMITRIL vs IMIPRAMINE PAMOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life: 15–25 hours (mean 20 h); may extend to >40 h in elderly or hepatic impairment.
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Renal: ~70% as metabolites, <5% unchanged; fecal: ~30% via bile.
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant